Early changes in renal function after sodium-glucose cotransporter 2 inhibitor initiation in EMPEROR-Reduced: the end of the dilemma?

Publisher: Wiley Country of Publication: England NLM ID: 100887595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0844 (Electronic) Linking ISSN: 13889842 NLM ISO Abbreviation: Eur J Heart Fail Subsets: MEDLINE

Publication: 2014- : Chichester : Wiley
Original Publication: Amsterdam ; New York : Elsevier Science, c1999-

Heart Failure* ; Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Diabetes Mellitus, Type 2*/drug therapy; Humans ; Glucose ; Kidney/physiology ; Sodium

Comment on: Eur J Heart Fail. 2022 Oct;24(10):1829-1839. (PMID: 35711093)

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24.
Adamson C, Docherty KF, Heerspink HJL, de Boer RA, Damman K, Inzucchi SE, et al. Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation. 2022;146:438-49.
Verma S, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos G, et al.; EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes Endocrinol. 2022;10:35-45.
Mullens W, Martens P, Testani JM, Tang WHW, Skouri H, Verbrugge FH, et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24:603-19.
van Bommel EJM, Lytvyn Y, Perkins BA, Soleymanlou N, Fagan NM, Koitka-Weber A, et al. Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function. Kidney Int. 2020;97:631-5.
Lytvyn Y, Kimura K, Peter N, Lai V, Tse J, Cham L, et al. Renal and vascular effects of combined SGLT2 and angiotensin-converting enzyme inhibition. Circulation. 2022;146:450-62.
ClinicalTrials.gov. ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure (NCT03416270). https://clinicaltrials.gov/ct2/show/NCT03416270 (accessed 29 August 2022).
Zannad F, Ferreira JP, Gregson J, Kraus BJ, Mattheus M, Hauske SJ, et al. Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced. Eur J Heart Fail. 2022;24:1829-39.
European Medicines Agency. ICH E9 Statistical Principles for Clinical Trials (CPMP/ICH/363/96). https://www.ema.europa.eu/en/ich-e9-statistical-principles-clinical-trials (accessed 29 August 2022).
Beldhuis IE, Lam CSP, Testani JM, Voors AA, Van Spall HGC, Ter Maaten JM, et al. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation. 2022;145:693-712.

0 (Sodium-Glucose Transporter 2 Inhibitors)
IY9XDZ35W2 (Glucose)
9NEZ333N27 (Sodium)

Date Created: 20220823 Date Completed: 20221128 Latest Revision: 20221220

20240628

10.1002/ejhf.2659

35999649